| ［1］ |
Rödel C, Graeven U, Fietkau R, et al.Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre,open-label, randomised, phase 3 trial ［J］.Lancet Oncol, 2015,16(8): 979-989.
|
| ［2］ |
Sauer R, Liersch T, Merkel S, et al.Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phaseⅢtrial after a median follow-up of 11 years ［J］.J Clin Oncol, 2012, 30(16): 1926-1933.
|
| ［3］ |
Cercek A, Dos Santos Fernandes G, Roxburgh CS, et al.Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy ［J］.Clin Cancer Res, 2020, 26(13): 3271-3279.
|
| ［4］ |
André T, Shiu KK, Kim TW, et al.Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer ［J］.N Engl J Med, 2020, 383(23): 2207-2218.
|
| ［5］ |
Chalabi M, Verschoor YL, van den Berg J, et al.LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study［ J］.Annals of Oncology, 2022, 33: S1389.
|
| ［6］ |
Cercek A, Lumish M, Sinopoli J, et al.PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer［ J］.N Engl J Med, 2022, 386(25): 2363-2376.
|
| ［7］ |
Gelsomino F, Barbolini M, Spallanzani A, et al.The evolving role of microsatellite instability in colorectal cancer: A review［ J］.Cancer Treat Rev, 2016, 51: 19-26.
|
| ［8］ |
Chalabi M, Fanchi LF, Dijkstra KK, et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers［ J］.Nat Med, 2020,26(4): 566-576.
|
| ［9］ |
Wang Q, Shen X, Chen G, et al.How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation［ J］.Int J Cancer, 2023, 153(4): 709-722.
|
| ［10］ |
Yang Z, Wu G, Zhang X, et al.Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer［ J］.Front Immunol, 2022, 13:1001444.
|
| ［11］ |
Wang L, Lynch C, Pitroda SP, et al.Radiotherapy and immunology［ J］.J Exp Med, 2024, 221(7): e20232101.
|
| ［12］ |
Galluzzi L, Humeau J, Buqué A, et al.Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors［ J］.Nat Rev Clin Oncol, 2020, 17(12): 725-741.
|
| ［13］ |
Tesniere A, Schlemmer F, Boige V, et al.Immunogenic death of colon cancer cells treated with oxaliplatin［ J］.Oncogene, 2010,29(4): 482-491.
|
| ［14］ |
Dosset M, Vargas TR, Lagrange A, et al.PD-1/PD-L1 pathway:an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer［ J］.Oncoimmunology, 2018,7(6): e1433981.
|
| ［15］ |
Bando H, Tsukada Y, Inamori K, et al.Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer［ J］.Clin Cancer Res, 2022,28(6): 1136-1146.
|
| ［16］ |
Lin Z, Cai M, Zhang P, et al.Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer ［J］.J Immunother Cancer, 2021, 9(11): e003554.
|
| ［17］ |
Yang Z, Gao J, Zheng J, et al.Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study［ J］.Signal Transduct Target Ther, 2024, 9(1): 56.
|
| ［18］ |
Xiao WW, Chen G, Gao YH, et al.Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial［J］.Cancer Cell, 2024, 42(9):1570-1581.e4.
|
| ［19］ |
Yang Z, Ma J, Han J, et al.Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer［ J］.Med, 2024, 5(10): 1293-1306.e4.
|
| ［20］ |
Zhu C, Shi Y, Li Q, et al.Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect ［J］.J Control Release, 2022, 341: 769-781.
|
| ［21］ |
Aliru ML, Schoenhals JE, Venkatesulu BP, et al.Radiation therapy and immunotherapy: what is the optimal timing or sequencing?［ J］.Immunotherapy, 2018, 10(4): 299-316.
|
| ［22］ |
Yang L, Cui X, Wu F, et al.The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review［ J］.Front Immunol, 2024, 15: 1392499.
|
| ［23］ |
Grapin M, Richard C, Limagne E, et al.Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination［ J］.J Immunother Cancer, 2019, 7(1): 160.
|
| ［24］ |
Morisada M, Clavijo PE, Moore E, et al.PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation［ J］.Oncoimmunology, 2018, 7(3): e1395996.
|
| ［25］ |
Wang C, Zeng Q, Gül ZM, et al.Circadian tumor infiltration and function of CD8 + T cells dictate immunotherapy efficacy［ J］.Cell, 2024, 187(11): 2690-2702.e17.
|
| ［26］ |
Qian DC, Kleber T, Brammer B, et al.Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity scorematched analysis of a single-centre, longitudinal study ［J］.Lancet Oncol, 2021, 22(12): 1777-1786.
|
| ［27］ |
Rousseau A, Tagliamento M, Auclin E, et al.Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer［ J］.Eur J Cancer, 2023,182: 107-114.
|